Pathogenetic aspects of menstrual and reproductive disorders in obese women

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Obesity, which prevalence in Russia ranges from 24 to 36%, leads to negative consequences for reproductive health - menstrual cycle disorders (MCD) and infertility. The results of the study of the mechanisms of the obesity influence on the menstrual cycle, folliculogenesis and ovulation are still controversial.

Objective: Assessment of the metabolic, hormonal, immune, vitamin and mineral status in patients with obesity and determination of the most significant risk factors for menstrual and reproductive dysfunction.

Materials and methods: Design: a simple observational study. 70 patients were included: Group I (n=40) – with obesity and oligo-/amenorrhea-type MCD, and Group II (n=30, control) – healthy. Clinical and laboratory research methods, pelvic ultrasound and folliculometry were used.

Results: The age of the participants ranged from 20 to 37 years (mean – 27.9 (SD 3.8), p=0.99). The body mass index (BMI) in patients with obesity corresponded to stage I (32.1 kg/m2), oligomenorrhea occurred in 90% of them, amenorrhea – in 10%, heavy menstrual bleeding (HMB) in 85%, ovulation was recorded 2.5 times less frequently than in group II (35 versus 86.7%, respectively, OR 0.40, 95% CI: 0.23–0.26), and the risk of anovulation was 5 times higher, respectively (OR 4.88, 95% CI: 1.90–12.48). The profile of obese patients showed the following: insulin resistance (HOMA index – 3.1 c.u.), significant increase in the insulin (by 3 times), homocysteine ( by 2.4 times), CRP (by 6 times), leptin (by 6 times), free testosterone (by 3 times), DHEA-S (by 1.4 times), cytokines (by 6 times on average) levels, decreased levels of HDL and LH (both – by 1.5 times), folic acid (by 3 times), manganese and 25-hydroxycalciferol (by 2 times) compared to the control group. Based on the analysis of the principal components, it was established that the factor loadings of the key markers reflected a greater contribution of the metabolic factor and, to a lesser extent, the hormonal factor in the formation of anovulation in obese patients. The most significant risk factors for anovulation were insulin resistance and leptin, insulin, triglycerides, LDL levels above the reference values and HDL level below the reference values. Among the hormonal profile parameters, the key marker of anovulation was a decrease in LH levels in combination with low serum folate concentrations. The inflammatory status typical for obese patients was associated with MCD but did not affect ovulatory function.

Conclusion: In patients with stage I obesity, metabolic disorders play a leading role in the pathogenesis of MCD and anovulation, and hormonal disorders play a lesser role.

Full Text

Restricted Access

About the authors

Ramina M. Efendieva

Dagestan State Medical University

Author for correspondence.
Email: romidok@mail.ru
ORCID iD: 0009-0002-1729-4781

Postgraduate Student, Department of Obstetrics and Gynecology, Faculty of Medicine

Russian Federation, Makhachkala

Galina B. Dikke

Inozemtsev Academy of Medical Education

Email: galadikke@yandex.ru
ORCID iD: 0000-0001-9524-8962

Dr. Sci. (Med.), Professor, Department of Obstetrics and Gynecology with the Course of Reproductive Medicine

Russian Federation, St. Petersburg

Zukhra A. Abusueva

Dagestan State Medical University

Email: zuhraabusueva@mail.ru
ORCID iD: 0000-0002-7729-1606

Dr.Sci. (Med.), Professor, Department of Obstetrics and Gynecology, Faculty of Medicine

Russian Federation, Makhachkala

Natalia V. Shilova

National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)

Email: nvshilova@gmail.com
ORCID iD: 0000-0001-6734-0147

Cand. Sci. (Med.), Associate Professor, Department of Industrial Pharmacy

Russian Federation, Moscow

References

  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2
  2. WHO. The Global Health Observatory: Prevalence of obesity among adults. [As of May 27, 2024]. WHO, 2024.
  3. Алфёрова В.И., Мустафина С.В. Распространенность ожирения во взрослой популяции Российской Федерации (обзор литературы). Ожирение и метаболизм. 2022;19(1):96–105 [Alferova V.I., Mustafina S.V. Prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and Metabolism. 2022;19(1):96–105 (In Russ.)]. https://doi.org/10.14341/omet12809
  4. Muscogiuri G., Verde L., Vetrani C., et al. Obesity: a gender-view. J Endocrinol Invest. 2024;47(2):299–306. https://doi.org/10.1007/s40618-023-02196-z
  5. Powell-Wiley T.M., Poirier P., Burke L.E., et al; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010. https://doi.org/10.1161/CIR.0000000000000973
  6. Collée J., Mawet M., Tebache L., et al. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol Endocrinol. 2021;37(10):869–874. https://doi.org/10.1080/09513590.2021.1958310
  7. Annarahayu L., Dewi Y.L.R., Adriyani R.B. Meta-analysis the effect of obesity and stress on menstrual cycle disorder. J Matern Child Health. 2021;06(04):423–435. https://doi.org/10.26911/thejmch.2021.06.04.0
  8. Sermondade N., Huberlant S., Bourhis-Lefebvre V., et al. Female obesity is negatively associated with live birth rate following IVF: a systematic review and meta-analysis. Hum Reprod Update. 2019; 25(4):439–451. https://doi.org/10.1093/humupd/dmz011
  9. Westerman R., Kuhnt A.K. Metabolic risk factors and fertility disorders: A narrative review of the female perspective. Reprod Biomed Soc Online. 2021;14:66–74. https://doi.org/10.1016/j.rbms.2021.09.002
  10. Zheng L., Yang L., Guo Z., et al. Obesity and its impact on female reproductive health: unraveling the connections. Front Endocrinol (Lausanne). 2024;14:1326546. https://doi.org/10.3389/fendo.2023.1326546
  11. Hunter E., Avenell A., Maheshwari A., et al. The effectiveness of weight-loss lifestyle interventions for improving fertility in women and men with overweight or obesity and infertility: A systematic review update of evidence from randomized controlled trials. Obes Rev. 2021 Dec; 22(12):e13325. https://doi.org/10.1111/obr.13325
  12. Memon Е., Aamir F., Waheed А., et al. Association of Menstrual Irregularity with Obesity Erum Memon. Rawal Medical Journal. 2022;47(3):591–595.
  13. Zhou X., Yang X. Association between obesity and oligomenorrhea or irregular menstruation in Chinese women of childbearing age: a cross-sectional study. Gynecol Endocrinol. 2020;36(12):1101–1105. https://doi.org/10.1080/09513590.2020.1803823
  14. Ведзижева Э.Р., Кузнецова И.В. Репродуктивное здоровье женщин с расстройствами жирового обмена. Медицинский алфавит. 2020;(4):27–32 [Vedzizheva E.R., Kuznetsova I.V. Reproductive health of women with fat metabolism disorders. Medical alphabet. 2020;(4):27–32 (In Russ.)]. https://doi.org/10.33667/2078-5631-2020-4-27-32
  15. Артымук Н.В., Тачкова О.А., Сухова Н.А. Влияние диетотерапии на динамику антропометрических и основных метаболических показателей у бесплодных женщин с ожирением. Акушерство, гинекология и репродукция. 2020;14(1):7–14 [Artymuk N.V., Tachkova O.A., Sukhova N.A. The effect of diet therapy on the anthropometric and metabolic parameters in women with infertility and obesity. Akusherstvo, Ginekologia i Reprodukcia = Obstetrics, Gynecology and Reproduction. 2020;14(1):7–14 (In Russ.)]. https://doi.org/10.17749/2313-7347.2020.14.1.7-14
  16. Reavey J.J., Walker C., Murray A.A., et al. Obesity is associated with heavy menstruation that may be due to delayed endometrial repair. J Endocrinol. 2021;249(2):71–82. https://doi.org/10.1530/JOE-20-0446
  17. Sen L.C., Annee I.J., Akter N., et al. Study on relationship between obesity and menstrual disorders. Asian J. Med. Biol. Res. 2018;4(3):259–266. https://doi.org/10.3329/ajmbr.v4i3.38464
  18. Tang Y., Chen Y., Feng H., et al. Is body mass index associated with irregular menstruation: a questionnaire study? BMC Womens Health. 2020;20(1):226. https://doi.org/10.1186/s12905-020-01085-4
  19. Pita-Rodriguez G.M., Basabe-Tuero B., Diaz-Sanchez M.E., et al. Prevalence of anemia and iron deficiency in women of reproductive age in Cuba and associated factors. Int J Environ Res Public Health. 2023;20(6):5110. doi: 10.3390/ijerph20065110
  20. Rachmah Q., Mondal P., Phung H., Ahmed F. Association between overweight/obesity and iron deficiency anaemia among women of reproductive age: a systematic review. Public Health Nutr. 2024;27(1):e176. https://doi.org/10.1017/S1368980024001794
  21. Zhang C.H., Liu X.Y., Wang J. Essential role of granulosa cell glucose and lipid metabolism on oocytes and the potential metabolic imbalance in polycystic ovary syndrome. Int J Mol Sci. 2023 Nov;24(22):16247. https://doi.org/10.3390/ijms242216247
  22. Lin Y., Fan R., Hao Z., et al. The association between physical activity and insulin level under different levels of lipid indices and serum uric acid. Front Physiol. 2022;13:809669. https://doi.org/10.3389/fphys.2022.809669
  23. Arias A., Quiroz A., Santander N., et al. Implications of high-density cholesterol metabolism for oocyte biology and female fertility. Front Cell Dev Biol. 2022;10:941539. https://doi.org/10.3389/fcell.2022.941539
  24. Carter-Febres M., Fenchel M., Pomales J., et al. Hemoglobin concentration and body mass index are determinants of plasma von Willebrand factor and factor VIII levels. Thrombosis Research. 2024;240:109061. https://doi.org/10.1016/j.thromres.2024.109061
  25. Kojta I., Chacińska M., Błachnio-Zabielska A. Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients. 2020;12(5):1305. https://doi.org/10.3390/nu12051305
  26. Stoica R.A., Drăgana N., Ancuceanu R., et al. Interleukin-8, CXCL10, CXCL11 and their role in insulin resistance in adult females with subclinical hypothyroidism and prediabetes. J Clin Transl Endocrinol. 2022;28:100299. https://doi.org/10.1016/j.jcte.2022.100299
  27. Auguet T., Bertran L., Binetti J., et al. Relationship between IL-8 circulating levels and TLR2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21(11):4189. https://doi.org/10.3390/ijms21114189
  28. Eswar S., Rajagopalan B., Ete K., Gattem S.N.R. Clinical and biochemical parameters in relation to serum fetuin-A levels in overweight and obese with and without metabolic syndrome in the North-eastern States of Indian population. JMA J. 2024;7(4):529–535. https://doi.org/10.31662/jmaj.2024-0104
  29. Al Khathlan N. Association of inflammatory cytokines with obesity and pulmonary function testing. PLoS One. 2023;18(11):e0294592. https://doi.org/10.1371/journal.pone.0294592
  30. Solleiro-Villavicencio H., Mendez-Garcia L.A., Ocampo-Aguilera N.A., et al. Decreased hepatic and serum levels of IL-10 concur with increased lobular inflammation in morbidly obese patients. Medicina (Kaunas). 2024;60(6):862. https://doi.org/10.3390/medicina60060862
  31. Lei R., Chen S., Li W. Advances in the study of the correlation between insulin resistance and infertility. Front Endocrinol (Lausanne). 2024;15:1288326. https://doi.org/10.3389/fendo.2024.1288326
  32. Shay J.E.S., Singh A. The effect of obesity on gastrointestinal disease. Gastroenterol Clin North Am. 2023;52(2):403–415. https://doi.org/10.1016/j.gtc.2023.03.008
  33. Obradovic M., Sudar-Milovanovic E., Soskic S., et al. Leptin and obesity: role and clinical implication. Front Endocrinol (Lausanne). 2021;12:585887. https://doi.org/10.3389/fendo.2021.585887
  34. Eng P.C., Phylactou M., Qayum A., et al. Obesity-related hypogonadism in women. Endocr Rev. 2024;45(2):171–189. https://doi.org/10.1210/endrev/bnad027
  35. Kadir M., Hood R.B., Mínguez-Alarcón L., et al; EARTH Study Team. Folate intake and ovarian reserve among women attending a fertility center. Fertil Steril. 2022; 117(1):171–180. https://doi.org/10.1016/j.fertnstert.2021.09.037
  36. Торшин И.Ю., Громова О.А., Тетруашвили Н.К. и др. Метрический анализ соотношений коморбидности между невынашиванием, эндометриозом, нарушениями менструального цикла и микронутриентной обеспеченностью в скрининге женщин репродуктивного возраста. Акушерство и гинекология. 2019;5:156–168. [Torshin I.Yu., Gromova O.A., Tetruashvili N.K. et al. Metric analysis of comorbidity ratios between miscarriage, endometriosis, menstrual disorders, and micronutrient provision in screening reproductive-aged women. Akush Ginekol (Mosk). 2019;5:156–168. (In Russ.)]. https://doi.org/10.18565/aig.2019.5.156-168
  37. Громова О.А., Андреева Е.Н., Торшин И.Ю. и др. Системно-биологический анализ ролей марганца в акушерстве и гинекологии: репродуктивное здоровье женщины, регуляция менструального цикла и профилактика пороков развития плода. Вопросы гинекологии, акушерства и перинатологии. 2020;19(1):103–113 [Gromova O.A., Andreeva E.N., Torshin I.Yu. et al. A systemic biological analysis of the role of manganese in obstetrics and gynaecology: women’s reproductive health, menstrual cycle regulation and prevention of fetal malformations. Voprosy ginekologii, akusherstva i perinatologii 2020;19(1):103–113. (In Russ.)]. https://doi.org/10.20953/1726-1678-2020-1-103-113
  38. Karampela I., Sakelliou A., Vallianou N., et al. Vitamin D and obesity: current evidence and controversies. Curr Obes Rep. 2021;10(2):162–180. https://doi.org/10.1007/s13679-021-00433-1
  39. Piuri G., Zocchi M., Della Porta M., et al. Magnesium in obesity, metabolic syndrome, and type 2 diabetes. Nutrients. 2021;13(2):320. https://doi.org/10.3390/nu13020320
  40. Xu M.R., Wang A.P., Wang Y.J., et al. Serum magnesium levels are negatively associated with obesity and abdominal obesity in type 2 diabetes mellitus: a real-world study. Diabetes Metab J. 2024;48(6):1147–1159. https://doi.org/10.4093/dmj.2023.0401

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media